Show simple item record

dc.contributor.authorAsakra, Ren_US
dc.contributor.authorZaidi, Sen_US
dc.contributor.authorThway, Ken_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2018-02-19T11:08:22Z
dc.date.issued2017-12en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28697683en_US
dc.identifier.citationInt J Surg Pathol, 2017, 25 (8), pp. 702 - 704en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1274
dc.identifier.eissn1940-2465en_US
dc.identifier.doi10.1177/1066896917720727en_US
dc.description.abstractSclerosing epithelioid fibrosarcoma (SEF) is an aggressive neoplasm thought to be related to low-grade fibromyxoid sarcoma, which typically occurs in middle-aged adults in the deep soft tissues of the lower extremities and trunk. It comprises nests and cords of relatively uniform epithelioid polygonal cells with clear or eosinophilic cytoplasm in densely sclerotic stroma, and it is typically associated with EWSR1 gene rearrangements, and most commonly EWSR1-CREB3L1 fusions. As primary SEF can arise in bone, and bone is also a common metastatic site for SEF, its recognition at this site is important. We illustrate bone marrow showing diffuse infiltration by SEF and highlight the potential for confusion with a range of neoplasms such as carcinoma, hematolymphoid neoplasms, and other sarcomas.en_US
dc.format.extent702 - 704en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectEWSR1-CREB3L1en_US
dc.subjectbone marrowen_US
dc.subjectlow-grade fibromyxoid sarcomaen_US
dc.subjectmetastasisen_US
dc.subjectsarcomaen_US
dc.subjectsclerosing epithelioid fibrosarcomaen_US
dc.subjectAbdominal Wallen_US
dc.subjectBone Marrow Neoplasmsen_US
dc.subjectDiagnosis, Differentialen_US
dc.subjectEpithelioid Cellsen_US
dc.subjectFibrosarcomaen_US
dc.subjectHumansen_US
dc.subjectSarcomaen_US
dc.subjectSoft Tissue Neoplasmsen_US
dc.titleMetastatic Sclerosing Epithelioid Fibrosarcoma in Bone Marrow.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1177/1066896917720727en_US
rioxxterms.licenseref.startdate2017-12en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfInt J Surg Patholen_US
pubs.issue8en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume25en_US
pubs.embargo.termsNot knownen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorZaidi, Shane Haideren_US
dc.contributor.icrauthorThway, Khinen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record